Soluble Programmed Cell Death-1 is a Novel Predictor of HBsAg Loss in Chronic Hepatitis B Patients When Long-Term Nucleos(t)ide Analog Treatment is Discontinued

References

• Terrault NA, Bzowej NH, Chang K, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–283. doi:10.1002/hep.28156
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address:[email protected]; European Association for the Study of the Liver: EASL2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.021
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98. doi:10.1007/s12072-015-9675-4
   PubMed Web of Science ®Google Scholar
• van Boemmel F, Berg T. Risks and Benefits of discontinuation of nucleos(t)ide analogue treatment: a treatment concept for patients with HBeAg-negative chronic hepatitis B. Hepatol Commun. 2021;5:1632–1648. doi:10.1002/hep4.1708
   Web of Science ®Google Scholar
• Papatheodoridi M, Papatheodoridis G:. Emerging diagnostic tools to decide when to discontinue nucleos(t)ide analogues in chronic hepatitis B. Cells-Basel. 2020;9:493.
   Web of Science ®Google Scholar
• Xie Y, Li M, Ou X, et al. HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation. J Gastroenterol. 2021;56:856–867. doi:10.1007/s00535-021-01812-0
   Web of Science ®Google Scholar
• Mak LY, Wong DKH, Cheung KS, et al. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharm Ther. 2018;47:43–54. doi:10.1111/apt.14376
   PubMed Web of Science ®Google Scholar
• Rivino L, Le Bert N, Gill US, et al. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. J Clin Invest. 2018;128:668–681. doi:10.1172/JCI92812
   PubMed Web of Science ®Google Scholar
• Park J, Wong DK, Wahed AS, et al. Hepatitis B virus-specific and global T-cell dysfunction in chronic hepatitis B. Gastroenterology. 2016;150:684.
   PubMed Web of Science ®Google Scholar
• Chang K, Traum D, Park J, et al. Distinct phenotype and function of circulating V1(+) and V2(+) T-cells in acute and chronic hepatitis B. PLoS Pathog. 2019;15(4):e1007715. doi:10.1371/journal.ppat.1007715
   Web of Science ®Google Scholar
• Peng G, Li S, Wu W, et al. PD-1 upregulation is associated with HBV specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol. 2008;45(4):963–970. doi:10.1016/j.molimm.2007.07.038
   PubMed Web of Science ®Google Scholar
• Rinker F, Zimmer CL, Honer ZSC, et al. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J Hepatol. 2018;69(3):584–593. doi:10.1016/j.jhep.2018.05.004
   PubMed Web of Science ®Google Scholar
• Pen JJ, Keersmaecker BD, Heirman C, et al. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Ther. 2014;21:262–271. doi:10.1038/gt.2013.80
   PubMed Web of Science ®Google Scholar
• Khan M, Zhao Z, Arooj S, Fu Y, Liao G, Soluble PD-1. Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy. Front Immunol. 2020;11:11. doi:10.3389/fimmu.2020.00011
   Web of Science ®Google Scholar
• Meyo MT, Jouinot A, Giroux-Leprieur E, et al. Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for nivolumab therapy in advanced non-small cell lung cancer: a case-control study. Cancers. 2020;12:473.
   PubMed Web of Science ®Google Scholar
• Dong MP, Enomoto M, Thuy LTT, et al. Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma. Sci Rep-UK. 2020;10:1–10.
   Web of Science ®Google Scholar
• Cheng H, Kang P, Chuang Y, et al. Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma. PLoS One. 2014;9(11):e95870. doi:10.1371/journal.pone.0095870
   PubMed Web of Science ®Google Scholar
• Xia J, Huang R, Chen Y, et al. Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment. Aliment Pharm Ther. 2020;51(11):1180–1187. doi:10.1111/apt.15732
   Web of Science ®Google Scholar
• Zhou L, Li X, Huang X, et al. Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B. J Viral Hepatitis. 2019;26(7):795–802. doi:10.1111/jvh.13055
   Web of Science ®Google Scholar
• Tan N, Luo H, Kang Q, et al. Soluble programmed death-1 is predictive of hepatitis B surface antigen loss in chronic hepatitis B patients after antiviral treatment. World J Clin Cases. 2021;9(21):5812–5821. doi:10.12998/wjcc.v9.i21.5812
   Web of Science ®Google Scholar
• Li N, Zhou Z, Li F, et al. Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection. Oncotarget. 2017;8(28):46020–46033. doi:10.18632/oncotarget.17546
   PubMedGoogle Scholar
• Wang D, Du Q, Luo G, et al. Aberrant production of soluble inducible T cell co-stimulator and soluble programmed cell death protein 1 in patients with chronic hepatitis B. Mol Med Rep. 2017;16(6):8556–8562. doi:10.3892/mmr.2017.7630
   Web of Science ®Google Scholar
• Cao J, Chi H, Yu T, et al. Off-treatment hepatitis B virus (HBV) DNA levels and the prediction of relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B: a prospective stop study. J Infect Dis. 2017;215(4):581–589. doi:10.1093/infdis/jix025
   PubMed Web of Science ®Google Scholar
• Xia M, Liao G, Chen H, et al. Plasma CXCL13 is a predictive factor for HBsAg loss and clinical relapse after discontinuation of nucleos(t)ide analogue treatment. Clin Immunol. 2019;198:31–38. doi:10.1016/j.clim.2018.11.016
   PubMed Web of Science ®Google Scholar
• Jeng W, Chen Y, Chien R, Sheen I, Liaw Y. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2018;68(2):425–434. doi:10.1002/hep.29640
   PubMed Web of Science ®Google Scholar
• Berg T, Lampertico P. The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy. J Hepatol. 2021;75:474–480. doi:10.1016/j.jhep.2021.04.040
   PubMed Web of Science ®Google Scholar
• Bert F, Rossol S. Acute exacerbation of reactivated chronic hepatitis-b after stopping antiviral medication followed by loss of HBsAg. Deut Med Wochenschr. 2020;145:552–554.
   Web of Science ®Google Scholar
• Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology. 2012;143:963–973.e9. doi:10.1053/j.gastro.2012.07.014
   PubMed Web of Science ®Google Scholar
• Liu J, Li T, Zhang L, Xu A. The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among asian patients with chronic hepatitis B: a systematic review. Hepatology. 2019;70(3):1045–1055. doi:10.1002/hep.30474
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Ferrari C. Adaptive immunity in HBV infection. J Hepatol. 2016;641:S71–S83. doi:10.1016/j.jhep.2016.01.026
   Web of Science ®Google Scholar
• Bengsch B, Martin B, Thimme R. Restoration of HBV-specific CD8+T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J Hepatol. 2014;61:1212–1219. doi:10.1016/j.jhep.2014.07.005
   PubMed Web of Science ®Google Scholar
• Nielsen C, Ohm-Laursen L, Barington T, Husby S, Lillevang ST. Alternative splice variants of the human PD-1 gene. Cell Immunol. 2005;235(2):109–116. doi:10.1016/j.cellimm.2005.07.007
   PubMed Web of Science ®Google Scholar
• Song M, Park S, Nam HJ, Choi D, Sung Y. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1. J Immunother. 2011;34:297–306. doi:10.1097/CJI.0b013e318210ed0e
   PubMed Web of Science ®Google Scholar
• Berg T, Simon K, Mauss S, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. J Hepatol. 2017;67:918–924. doi:10.1016/j.jhep.2017.07.012
   PubMed Web of Science ®Google Scholar
• Tan N, Luo H, Kang Q, et al. High levels of soluble programmed death-1 are associated with virological response in chronic hepatitis B patients after antiviral treatment. Virus Res. 2022;309:198660. doi:10.1016/j.virusres.2021.198660
   Web of Science ®Google Scholar
• Wang D, Zhou D, Du Q, et al. Aberrant production of soluble inducible T-cell co-stimulator (sICOS) and soluble programmed cell death protein 1 (sPD-1) in patients with chronic hepatitis C. Mol Med Rep. 2013;7:1197–1202. doi:10.3892/mmr.2013.1326
   PubMed Web of Science ®Google Scholar
• Gu D, Ao X, Yang Y, Chen Z, Xu X. Soluble immune checkpoints in cancer: production, function and biological significance. J Immunother Cancer. 2018;6(1):1–8. doi:10.1186/s40425-018-0317-y
   Web of Science ®Google Scholar
• Greisen SR, Rasmussen TK, Stengaard-Pedersen K, et al. Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. Scand J Rheumatol. 2014;43(2):101–108. doi:10.3109/03009742.2013.823517
   PubMed Web of Science ®Google Scholar
• Bian B, Fanale D, Dusetti N, et al. Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. Oncoimmunology. 2019;8:e1561120.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Jia Y, Li C, Shao R, Fang Y. Predictive value of soluble programmed death-1 for severe sepsis and septic shock during the first week in an intensive care unit. Shock. 2019;51(3):289–297. doi:10.1097/SHK.0000000000001171
   Web of Science ®Google Scholar
• Pan S, Su W, Chan Y, et al. Disease progression in patients with nontuberculous mycobacterial lung disease of nodular bronchiectatic (NB) pattern: the role of cavitary NB and soluble programmed death protein-1. Clin Infect Dis. 2021:ciab929. PMID: 34726741. doi:10.1093/cid/ciab929
   Web of Science ®Google Scholar
• Incorvaia L, Fanale D, Badalamenti G, et al. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. Oncoimmunology. 2020;9:1832348.
   Web of Science ®Google Scholar
• Sorensen SF, Demuth C, Weber B, Sorensen BS, Meldgaard P. Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib. Lung Cancer. 2016;100:77–84. doi:10.1016/j.lungcan.2016.08.001
   PubMed Web of Science ®Google Scholar
• Chang B, Huang T, Wei H, et al. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. Cancer Immunol Immun. 2019;68:353–363. doi:10.1007/s00262-018-2271-4
   PubMed Web of Science ®Google Scholar